Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Total Liabilities (2018 - 2025)

Addex Therapeutics' Total Liabilities history spans 8 years, with the latest figure at $2.0 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 74.92% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a 74.92% increase, with the full-year FY2025 number at $1.9 million, up 68.63% from a year prior.
  • Total Liabilities came in at $2.0 million for Q4 2025, up from $1.7 million in the prior quarter.
  • The five-year high for Total Liabilities was $6.8 million in Q1 2021, with the low at $1.1 million in Q4 2024.
  • Historically, Total Liabilities has averaged $3.5 million across 5 years, with a median of $3.5 million in 2022.
  • Peak annual rise in Total Liabilities hit 74.92% in 2025, while the deepest fall reached 75.49% in 2025.
  • Year by year, Total Liabilities stood at $6.1 million in 2021, then plummeted by 42.52% to $3.5 million in 2022, then rose by 12.71% to $3.9 million in 2023, then plummeted by 71.01% to $1.1 million in 2024, then soared by 74.92% to $2.0 million in 2025.
  • Business Quant data shows Total Liabilities for ADXN at $2.0 million in Q4 2025, $1.7 million in Q3 2025, and $1.6 million in Q2 2025.